Literature DB >> 27936

Neuromuscular blockade of fazadinium bromide (AH 8165) in renal failure patients.

F Camu, A D'Hollander.   

Abstract

Fazadinium bromide (AH 8165) is a new non-depolarizing neuromuscular blocking agent with rapid onset of action and intermediate duration of effect. The characteristics of the neuromuscular blockade induced were compared in normal and renal failure patients by monitoring the mechanical responses of thumb adductor muscle to ulnar nerve stimulation. The data suggest that renal failure, even in anephric patients, does not influence the depth of neuromuscular relaxation when judged from the identical dose-effect curves in both groups of patients. Moreover, the duration of the neuromuscular block was not significantly increased in end-stage kidney failure patients, whether the initial or late phases of the spontaneous recovery of neuromuscular transmission were considered, and this occurred over the entire therapeutic range. However, additional incremental injections of fazadinium bromide should be used cautiously, as evidence appeared of prolonged duration of action. This agent, fazadinium bromide, may therefore present useful advantages to other non-depolarizing neuromuscular blocking agents as to clinical safety and effects in patients with renal insufficiency.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 27936     DOI: 10.1111/aas.1978.22.3.221

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  4 in total

Review 1.  Influence of renal and hepatic function on pharmacodynamics and pharmacokinetics of non-depolarizing muscle relaxants.

Authors:  L H Booij
Journal:  Pharm Weekbl Sci       Date:  1987-04-24

Review 2.  Pharmacokinetics in intravenous anaesthetic practice.

Authors:  P Duvaldestin
Journal:  Clin Pharmacokinet       Date:  1981 Jan-Feb       Impact factor: 6.447

3.  Clinical pharmacokinetics and pharmacodynamics of fazadinium in renal failure.

Authors:  D R Bevan; J D D'Souza; J M Rouse; J Caldwell; R L Smith
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

4.  Analytical model of some pharmacokinetic and pharmacodynamic properties of fazadinium in man.

Authors:  A A d'Hollander; C Delcroix; P Duvaldestin; D Henzel; E Coussaert; J M Desmonts
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.